Coding and billing guide

2020-2021 INFLUENZA SEASON

Please see Important Safety Information and full Prescribing Information on pages 12-14.
Consider this your go-to resource for ensuring the use of appropriate CPT codes, checking recent NDC codes, coding appropriately based on payer, and more. When it comes to coding and billing for Seqirus vaccines, we’ve got you covered.

4. Code the Seqirus vaccine administered
5. Current National Drug Codes (NDCs)
6. Code for the administration service
7. FLUAD® QUADRIVALENT
8. FLUCELVAX® QUADRIVALENT
9. AFLURIA® QUADRIVALENT
10. Commonly asked questions
If your payer requires NDCs, confirm that you are using this year’s NDCs, as they change each year for influenza vaccines. The NDCs for the 2020-2021 influenza season are listed in the grid to the left. TriCare, some Medicaid agencies, commercial payers, and Medicare Administrative Contractors (MACs) require the use of an 11-digit NDC in addition to the CPT code on claims for influenza vaccines (eg, FLUAD QUADRIVALENT-70461-0120-03; the red number shows where the additional zero needs to be added to make an 11-digit format and is the same for all of our vaccines). Note there are two different NDCs, carton or syringe/vial (unit-of-use), per the US Food and Drug Administration (FDA). Record the NDC on the syringe/vial (unit-of-use) in the patient’s record, as per the standard procedure in your practice. Medicare, TriCare, and many commercial payers use the carton NDC for claims processing/reimbursement. For assistance with NDCs, call flu360 | Support at 855-358-8966, option 3.

DISCLAIMER: The coding and billing information contained in this document is presented as a resource and guide to coding and billing for FLUAD QUADRIVALENT, Influenza Vaccine (Adjuvanted), FLUAD (Influenza Vaccine, Adjuvanted), FLUCELVAX QUADRIVALENT (Influenza Vaccine), and AFLURIA QUADRIVALENT (Influenza Vaccine). Coding and billing information is gathered from several sources and is subject to change without notice. While every effort is made to ensure the accuracy of this information, appropriate coding and billing for healthcare services are the provider’s responsibility and should always be based on the patient’s clinical condition, services provided, and payer guidelines.

Please see Important Safety Information and Full Prescribing Information on pages 12-14.
Influenza vaccine International Classification of Diseases, Tenth Revision diagnosis codes

Below is a suggested International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code that may be appropriate when submitting claims for Seqirus vaccines and their administration. The code should be linked to both the vaccine and administration codes.

Modifier 25 is used to denote when a patient receives a significant, separately identifiable Evaluation and Management (E/M) service by the same physician on the same day of the procedure or other service. The E/M service may be prompted by the symptom or condition for which the procedure and/or service was provided, so different diagnoses are not required for reporting the E/M services on the same date.

Note: This modifier is not used to report an E/M service that resulted in a decision to perform surgery; see modifier 57. For significant, separately identifiable, non-E/M services on the same day, see modifier 59.

For any reimbursement-related questions, call flu360 | Support at 855-358-8966, option 3.

Refer to the following pages for coding and billing information specific to each Seqirus product.

Note: Medicare requires use of Healthcare Common Procedure Coding System (HCPCS) code G0008 for the preventive administration of an influenza vaccine. HCPCS code G0008 must be used when billing Medicare instead of the administration CPT codes, regardless of the patient age or provider counseling. Other payers may require the use of HCPCS G0008; check with your payer for preferred administration code.

Code for the administration service

The method of administration for Seqirus vaccines should be reported in addition to the vaccine product code. Assign the appropriate immunization administration code based on the documentation in the medical record. The following CPT codes are for vaccines administered via injection to individuals.

 Modifier 25 is used to denote when a patient receives a significant, separately identifiable Evaluation and Management (E/M) service by the same physician on the same day of the procedure or other service. The E/M service may be prompted by the symptom or condition for which the procedure and/or service was provided, so different diagnoses are not required for reporting the E/M services on the same date.

Note: This modifier is not used to report an E/M service that resulted in a decision to perform surgery; see modifier 57. For significant, separately identifiable, non-E/M services on the same day, see modifier 59.

For any reimbursement-related questions, call flu360 | Support at 855-358-8966, option 3.

Refer to the following pages for coding and billing information specific to each Seqirus product.

Note: Medicare requires use of Healthcare Common Procedure Coding System (HCPCS) code G0008 for the preventive administration of an influenza vaccine. HCPCS code G0008 must be used when billing Medicare instead of the administration CPT codes, regardless of the patient age or provider counseling. Other payers may require the use of HCPCS G0008; check with your payer for preferred administration code.

Please see Important Safety Information and full Prescribing Information on pages 12-14.
A 34-year-old woman with a private health insurance plan is seen at the physician’s office for evaluation of her asthmatic condition and related prescription refills. The physician recommends she receive an influenza vaccine and administers FLUCELVAX QUADRIVALENT.1,3,5-8

A 28-year-old woman with a private health insurance plan is seen for a well visit and receives a needleless influenza vaccination, AFLURIA QUADRIVALENT.1,5-9

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the “N4” qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier “ML” for milliliter and the quantity as shown in the shaded area.

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration.

If required by payer, 11-digit NDC format using the carton NDC. If payer requires NDC, use the “N4” qualifier immediately followed by the 11-digit carton NDC, followed by the qualifier “ML” for milliliter and the quantity as shown in the shaded area.

Refer back to the appropriate diagnosis code on each line, including the vaccine and the vaccine administration.

Sample Claim Form Sample Claim Form

Please see Important Safety Information and Full Prescribing Information on pages 12-14.
When it comes to coding and billing, accuracy matters.

Q: Why are there two CPT codes for FLUAD®? Which one should I use?
A: The American Medical Association (AMA) established a new CPT code, 90694, for FLUAD QUADRIVALENT. It is important to use the appropriate CPT code to ensure proper payment. FLUAD QUADRIVALENT is the first-and-only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older. The appropriate CPT code for FLUAD QUADRIVALENT is:

CPT 90694, influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use

FLUAD is a standard-dose, three-component (trivalent) inactivated flu vaccine manufactured by Seqirus that contains MF59® adjuvant. FLUAD is designed specifically for adults 65+. The appropriate CPT code for FLUAD is:

CPT 90653, influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use

Q: When will we know the Medicare reimbursement rates for influenza vaccines? Where can I find the information?
A: The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician’s office or clinic are based on 95% of the Average Wholesale Price (AWP) as reflected in the published pricing compendia each year. You can locate this information by going to CMS.gov and typing “seasonal influenza vaccine reimbursement” into the search bar. All influenza vaccines will be listed on the CMS Medicare Fee for Service Vaccine pricing list by CPT code. Each flu season, CMS publishes the revised Medicare Part B fee for service vaccine pricing list for the flu season, typically in September of each year.

Q: What will Medicare reimburse for FLUAD® QUADRIVALENT?
A: FLUAD QUADRIVALENT is a covered benefit under Medicare Part B. CMS instructed the Medicare Administrative Contractors (MACs) to adopt the new CPT code, 90694 (influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use), effective July 1, 2020 to be available for the 2020-2021 influenza season. The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician’s office or clinic are based on 95% of Average Wholesale Price (AWP) as reflected in the published pricing compendia and are typically posted by CMS in September.

Q: Which NDC should I use: the one on the box or the one on the actual vial of vaccine?
A: Most but not all payers require an NDC number on an influenza vaccine claim. Medicare, TriCare, most commercial payers, and some state Medicaid agencies require the carton NDC for claims processing/reimbursement. If you are not sure, check with your payer to confirm their preferred NDC, either carton or unit-of-use. If you need assistance, call flu360 | Support at 855-358-8966, option 3.

Q: Can I code more than one unit of CPT 90694 if I administer flu and another vaccine at the same visit?
A: Yes. Where most primary codes can only be billed once per visit, CPT 90694 is different. You should bill a unit for the first (or only) component of each vaccine provided at each visit, while still meeting requirements to use the code.

Q: What reimbursement services are offered via flu360 | Support?
A: We assist healthcare providers in understanding the coding, coverage, and reimbursement requirements for all of Seqirus’ influenza vaccines. This includes verifying a patient’s insurance benefits, confirming payer requirements for coding, and if needed claims appeal support in the event of denied or underpaid claims. In the case of the new CPT code for FLUAD QUADRIVALENT we can confirm the payer has updated their fee schedule to include the new CPT code 90694.

Please see Important Safety Information and Full Prescribing Information on pages 12-14.

Commonly asked questions

Q: Why are there two CPT codes for FLUAD®? Which one should I use?
A: The American Medical Association (AMA) established a new CPT code, 90694, for FLUAD QUADRIVALENT. It is important to use the appropriate CPT code to ensure proper payment. FLUAD QUADRIVALENT is the first-and-only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older. The appropriate CPT code for FLUAD QUADRIVALENT is:

CPT 90694, influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use

FLUAD is a standard-dose, three-component (trivalent) inactivated flu vaccines manufactured by Seqirus that contains MF59® adjuvant. FLUAD is designed specifically for adults 65+. The appropriate CPT code for FLUAD is:

CPT 90653, influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use

Q: When will we know the Medicare reimbursement rates for influenza vaccines? Where can I find the information?
A: The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician’s office or clinic are based on 95% of the Average Wholesale Price (AWP) as reflected in the published pricing compendia each year. You can locate this information by going to CMS.gov and typing “seasonal influenza vaccine reimbursement” into the search bar. All influenza vaccines will be listed on the CMS Medicare Fee for Service Vaccine pricing list by CPT code. Each flu season, CMS publishes the revised Medicare Part B fee for service vaccine pricing list for the flu season, typically in September of each year.

Q: What will Medicare reimburse for FLUAD® QUADRIVALENT?
A: FLUAD QUADRIVALENT is a covered benefit under Medicare Part B. CMS instructed the Medicare Administrative Contractors (MACs) to adopt the new CPT code, 90694 (influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use), effective July 1, 2020 to be available for the 2020-2021 influenza season. The Medicare Part B payment allowances for seasonal influenza vaccines provided in the physician’s office or clinic are based on 95% of Average Wholesale Price (AWP) as reflected in the published pricing compendia and are typically posted by CMS in September.

Q: Which NDC should I use: the one on the box or the one on the actual vial of vaccine?
A: Most but not all payers require an NDC number on an influenza vaccine claim. Medicare, TriCare, most commercial payers, and some state Medicaid agencies require the carton NDC for claims processing/reimbursement. If you are not sure, check with your payer to confirm their preferred NDC, either carton or unit-of-use. If you need assistance, call flu360 | Support at 855-358-8966, option 3.

Q: Can I code more than one unit of CPT 90694 if I administer flu and another vaccine at the same visit?
A: Yes. Where most primary codes can only be billed once per visit, CPT 90694 is different. You should bill a unit for the first (or only) component of each vaccine provided at each visit, while still meeting requirements to use the code.

Q: What reimbursement services are offered via flu360 | Support?
A: We assist healthcare providers in understanding the coding, coverage, and reimbursement requirements for all of Seqirus’ influenza vaccines. This includes verifying a patient’s insurance benefits, confirming payer requirements for coding, and if needed claims appeal support in the event of denied or underpaid claims. In the case of the new CPT code for FLUAD QUADRIVALENT we can confirm the payer has updated their fee schedule to include the new CPT code 90694.
INDICATION AND USAGE
FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD and FLUAD QUADRIVALENT are approved for use in persons 65 years of age and older. These indications are approved under accelerated approval based on careful consideration of the potential benefits and risks.

CONTRAINDICATIONS
Do not administer FLUAD or FLUAD QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS
FLUAD® and FLUAD® QUADRIVALENT are registered trademarks of Seqirus UK Limited or its affiliates.

INDICATION AND USAGE
FLUCELVAX® QUADRIVALENT (Influenza Vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 16 years of age and older. For children 6 through 17 years of age, approval is based on the immune response elicited by FLUCELVAX QUADRIVALENT. Data demonstrating a decrease in influenza disease after vaccination of this age group with FLUCELVAX QUADRIVALENT are not available.

IMPORTANT SAFETY INFORMATION
To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-833-358-9694 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov . Before administration, please see the full Prescribing Information for FLUCELVAX QUADRIVALENT here.
INDICATION AND USAGE
 AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
 AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION
 CONTRAINDICATIONS
 AFLURIA QUADRIVALENT is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
 WARNINGS AND PRECAUTIONS
 If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous vaccination with AFLURIA QUADRIVALENT, FDA recommends caution when considering future influenza vaccinations, including those receiving immunosuppressive therapy, the immune response may be diminished.
 Vaccination with AFLURIA QUADRIVALENT may not protect all individuals.

ADVERSE REACTIONS
 AFLURIA QUADRIVALENT administered by needle and syringe:

In adults 65 years of age and older, the most commonly reported injection-site adverse reaction was pain (≥10%). The most common systemic adverse event was myalgia (≥10%).

In children 5 through 8 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In adults 18 through 64 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In children 9 through 17 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In children ≥25 months of age, the most commonly reported injection-site reactions were pain and redness (≥20%). The most common systemic adverse events were irritability (≥20%), diarrhea and loss of appetite (≥20%).

The most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet® device were pain (≥30%), swelling, redness, and bruising (≥20%). The most common systemic adverse events were myalgia, malaise and fatigue (≥20%), and headache (≥20%).

Adverse reactions with AFLURIA (trivalent formulation) when administered by the STRATIS® device were pain (≥40%). The most common systemic adverse event was headache, myalgia, and malaise and fatigue (≥40%).

In children 6 through 23 months of age, the most commonly reported injection-site reactions were pain and redness (≥20%). The most common systemic adverse events were irritation (≥20%), diarrhea, and loss of appetite (≥20%).

In adults 65 years of age and older, the most commonly reported injection-site adverse reaction was pain (≥10%). The most common systemic adverse event was myalgia (≥10%).

In children 5 through 8 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In adults 18 through 64 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In children 9 through 17 years, the most commonly reported injection-site adverse reactions were pain (≥10%), redness, and swelling (≥10%). The most common systemic adverse event was headache (≥10%).

In children ≥25 months of age, the most commonly reported injection-site reactions were pain and redness (≥20%). The most common systemic adverse events were irritability (≥20%), diarrhea and loss of appetite (≥20%).

The most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet® device were pain (≥30%), swelling, redness, and bruising (≥20%). The most common systemic adverse events were myalgia, malaise and fatigue (≥20%), and headache (≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc.

Reimbursement
Please see Important Safety Information and full Prescribing Information on pages 12-14.
flu360™ pairs our robust influenza product portfolio with the support you need.

3 easy ordering methods:

- Order online at flu.seqirus.com
- Email customer service at customerservice.us@seqirus.com
- Contact your Seqirus account manager about our portfolio of influenza vaccines and treatment

Questions?

Call flu360 | Support 855-358-8966, option 3